Bristol-Myers Squibb Co
featured
Stocks closed down 1 percent after the minutes from the last Fed policy setting meeting suggested the central bank could begin tapering bond purchases sooner than the market expects.
» Read More
More
-
NEW YORK, Dec 11- Teva Pharmaceutical Industries' new Chief Executive Jeremy Levin promised on Tuesday to reshape the company into "the most indispensable medicines company in the world" and to provide significant value to its shareholders along the way.
-
NEW YORK, Dec 11- Teva Pharmaceutical Industries' new Chief Executive Jeremy Levin promised on Tuesday to reshape the company into "the most indispensable medicines company in the world" and to provide significant value to its shareholders along the way.
-
*Teva meeting with investors, analysts Dec. 11 in New York. NEW YORK/ TEL AVIV, Dec 5- Teva Pharmaceutical Industries' new Chief Executive Jeremy Levin has promised investors it will be a very different company going forward.
-
Check out which companies are making headlines after the bell Tuesday:
-
*Early signs pipelines improving- Deloitte, Thomson Reuters. LONDON, Dec 4- Drug companies are becoming more efficient in hunting for new treatments, though this has yet to be reflected in improved investment returns, according to a report on Tuesday.
-
Nov 30- Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs, announced an ambitious plan to reshape the company on Friday aimed at streamlining operations, cutting costs and improving profitability.
-
*To outline its plans in detail on Dec. 11. Nov 30- Teva Pharmaceutical Industries Ltd, the world's biggest maker of generic drugs, announced an ambitious plan on Friday to reshape the company as it faces increased competition for its top-selling multiple sclerosis drug Copaxone.
-
Three of the top ten dividend stocks in the S&P are drug stocks. Will they lose out if dividend taxes rise?
-
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
-
*DOJ, SEC convinced enforcement changing corporate culture. At least eight of the world's top 10 drugmakers, including Bristol-Myers Squibb Co, Pfizer Inc and Johnson&, have disclosed U.S. probes under the 1977 Foreign Corrupt Practices Act.
-
TRENTON, N.J.-- Pfizer Inc., the world's biggest drugmaker by revenue, will focus on progress on key experimental drugs, recent drug approvals and its ongoing corporate makeover when it reports third-quarter results before the stock market opens Tuesday.
-
WASHINGTON, Oct 25- Boehringer Ingelheim Pharmaceuticals Inc agreed to pay $95 million to U.S. government agencies to settle civil allegations that it illegally marketed drugs for unapproved uses, the U.S. Justice Department said on T hur sday.
-
*Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. *Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.
-
*Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.
-
*Q3 sales fall 19 pct to $6.68 bln vs consensus $6.75 bln. Core EPS $1.51 vs consensus $1.44; full-year outlook held. LONDON, Oct 25- AstraZeneca's sales slumped by a bigger-than-expected 19 percent in the third quarter, underscoring the challenges confronting the drugmaker's new chief executive, Pascal Soriot.
-
BATON ROUGE, La.-- Louisiana Attorney General James "Buddy" Caldwell's office says five pharmaceutical companies will pay the state more than $18.6 million to resolve allegations they misreported drug price information to the state's Medicaid program.
-
*Dow down 0.2 pct, S&P 500 off 0.3 pct, Nasdaq off 0.3 pct. *Boeing dips after results, but Dow Chemical jumps on job-cut plans. The S&P 500 has lost 3.6 percent over the past five sessions, hurt by weak earnings outlooks and top-line revenue misses from large multinational companies.
-
Oct 24- Eli Lilly and Co and Bristol-Myers Squibb Co posted lower-than-expected profit as their former top medicines were pounded by cheaper generics and sales of other products disappointed, sending their shares lower. Lilly earned $1.33 billion, or $1.18 per share, in the third quarter. That compared with $1.24 billion or $1.11 per share a year earlier.
-
*China data points to strengthening recovery. *Dow Chemical to cut jobs. NEW YORK, Oct 24- U.S. stock index futures edged higher on Wednesday, indicating indexes may bounce from declines a day earlier when the Dow suffered its biggest drop in four months, following data from China that eased concerns about sluggish global growth.
